Last reviewed · How we verify
Group P+T
This drug works by inhibiting the P2Y12 receptor, preventing platelet activation and aggregation.
This drug works by inhibiting the P2Y12 receptor, preventing platelet activation and aggregation. Used for Atrial fibrillation for stroke prevention, Acute coronary syndrome.
At a glance
| Generic name | Group P+T |
|---|---|
| Sponsor | Huazhong University of Science and Technology |
| Drug class | P2Y12 inhibitor |
| Target | P2Y12 receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
By blocking the P2Y12 receptor, the drug reduces the formation of blood clots, which can cause heart attacks and strokes. This is particularly useful in patients with atrial fibrillation, who are at increased risk of stroke.
Approved indications
- Atrial fibrillation for stroke prevention
- Acute coronary syndrome
Common side effects
- Bleeding
- Thrombocytopenia
- Allergic reactions
Key clinical trials
- Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer (PHASE3)
- Screening Study of Combined Sequential Chemotherapy and Radiation Therapy for Early-stage NK/T-cell Lymphoma (PHASE2)
- Prophylactic Use of APRV Before Extubation in Morbidly Obese Patients After Cardiac Surgery. (NA)
- Ultrasound Evaluation of Two Anatomic Landmarks in Spinal Anesthesia for Cesarean Section: the Posterior Superior Iliac Spine VS Iliac Crest
- Phase IIa/b Trial of PvCS/Montanide ISA-51 Malaria Vaccine in Adults in Chocó, Colombia (PHASE2)
- Cardiac Autonomic and Anxiety Regulation Via Closed-loop nEurofeedback in Recurrent Pregnancy Loss (NA)
- Relationship Between Periodontal Disease and Postmenopausal Osteoporosis
- Nab-P+Cb+PD1 Inhibitors as Neoadjuvant Therapy for Early TNBC (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Group P+T CI brief — competitive landscape report
- Group P+T updates RSS · CI watch RSS
- Huazhong University of Science and Technology portfolio CI